AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24695896 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D₃
Number of subjects: 125
Study 23304689 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented implant-supported single crown
Number of subjects: 18
Study 23304689 — intervention group
Group type: COMPARATOR
Intervention: Screw-retained implant-supported single crown
Number of subjects: 18
Study 19941696 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 50 mg eq.
Number of subjects: 197
Study 19941696 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 100 mg eq.
Number of subjects: 197
Study 19941696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 19941696 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (both doses)
Number of subjects: 197
Study 19941696 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate
Number of subjects: 197
Study 17055609 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing spearmint gum
Number of subjects: 0
Study 17055609 — intervention group
Group type: COMPARATOR
Intervention: Control (no chewing gum)
Number of subjects: 0
Study 15958785 — intervention group
Group type: EXPERIMENTAL
Intervention: Injury prevention program based on physician-community partnerships and private foundation support
Number of subjects: 0
Study 12139269 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg plus codeine 30 mg
Number of subjects: 82
Study 12139269 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 1000 mg alone
Number of subjects: 82
Study 9865013 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic plasmapheresis (TP)
Number of subjects: 46
Study 9865013 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic plasmapheresis (TP) + alpha-tocopherol treatment (AT)
Number of subjects: 46
Study 8560531 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (4 mg/kg/d for 3 d) + mefloquine (25 mg/kg)
Number of subjects: 540
Study 8560531 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether (4 mg/kg/d for 3 d) + mefloquine (25 mg/kg)
Number of subjects: 540
Study 8560531 — intervention group
Group type: COMPARATOR
Intervention: Mefloquine alone (25 mg/kg)
Number of subjects: 540
Study 1696846 — intervention group
Group type: EXPERIMENTAL
Intervention: VAB-6 (cyclophosphamide + vinblastine + bleomycin + dactinomycin + cisplatin; 81 patients)
Number of subjects: 162
Study 1696846 — intervention group
Group type: COMPARATOR
Intervention: etoposide + cisplatin (EP; 81 patients)
Number of subjects: 162
Study 350262 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol, 40 mg three times daily
Number of subjects: 25
Study 350262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 31963239 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented dairy (yogurt and acidified milk)
Number of subjects: 23
Study 31963239 — intervention group
Group type: COMPARATOR
Intervention: Non-fermented dairy (milk and cheese)
Number of subjects: 23
Study 31793482 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA
Number of subjects: 110
Study 31793482 — intervention group
Group type: COMPARATOR
Intervention: DPNB
Number of subjects: 110
Study 28722100 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative-psychotherapeutic treatment program consisting of 16 weekly sessions including vestibular rehabilitation training and modules for anxiety, panic disorder, depression, and somatisation.
Number of subjects: 0
Study 28722100 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot trial
Number of subjects: 0
Study 26638592 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct field block with 40 ml of 0.125% bupivacaine
Number of subjects: 56
Study 26638592 — intervention group
Group type: COMPARATOR
Intervention: Spinal block with intrathecal morphine (Control)
Number of subjects: 56
Study 23941601 — intervention group
Group type: EXPERIMENTAL
Intervention: Poliglecaprone‐25
Number of subjects: 140
Study 23941601 — intervention group
Group type: COMPARATOR
Intervention: Polyglactin‐910
Number of subjects: 140
Study 21518010 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise
Number of subjects: 57
Study 21518010 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise
Number of subjects: 57
Study 21518010 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 57
Study 19147732 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day atorvastatin
Number of subjects: 2350
Study 19147732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2350
Study 17530496 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxious mood condition (anxiety-related coping motivated drinkers)
Number of subjects: 47
Study 17530496 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxious mood condition (enhancement-motivated drinkers)
Number of subjects: 47
Study 17530496 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive mood condition (enhancement-motivated participants)
Number of subjects: 47
Study 15631287 — intervention group
Group type: EXPERIMENTAL
Intervention: OVAT screening tool
Number of subjects: 306
Study 15631287 — intervention group
Group type: COMPARATOR
Intervention: ISA (Index of Spouse Abuse)
Number of subjects: 306
Study 11005043 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT with high dosage (2.5 times seizure threshold)
Number of subjects: 62
Study 11005043 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT with bilateral electrode placement
Number of subjects: 62
Study 11005043 — intervention group
Group type: COMPARATOR
Intervention: ECT with right unilateral electrode placement
Number of subjects: 62
Study 11005043 — intervention group
Group type: COMPARATOR
Intervention: ECT with stimulus dosage just above seizure threshold
Number of subjects: 62
Study 11005043 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical outcome following ECT
Number of subjects: 62
Study 11005043 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient age, initial seizure threshold, and baseline depression severity
Number of subjects: 62
Study 11005043 — intervention group
Group type: EXPERIMENTAL
Intervention: Postictal bioelectric suppression
Number of subjects: 62
Study 9483233 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous heparin (5000 unit bolus followed by 1000 units per hour, adjusted by nomogram)
Number of subjects: 108
Study 8368420 — intervention group
Group type: EXPERIMENTAL
Intervention: High-top shoes
Number of subjects: 622
Study 8368420 — intervention group
Group type: COMPARATOR
Intervention: Low-top shoes
Number of subjects: 622
Study 8368420 — intervention group
Group type: COMPARATOR
Intervention: High-top shoes with inflatable air chambers
Number of subjects: 622
Study 3792362 — intervention group
Group type: EXPERIMENTAL
Intervention: 111In-platelet scintigraphy
Number of subjects: 40
Study 3792362 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dimensional echocardiography
Number of subjects: 40
Study 3792362 — intervention group
Group type: EXPERIMENTAL
Intervention: 111In-platelet scintigraphy and two-dimensional echocardiography
Number of subjects: 40
Study 31498898 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (specific details not provided)
Number of subjects: 521
Study 28535410 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel 1mg alone
Number of subjects: 26
Study 28535410 — intervention group
Group type: COMPARATOR
Intervention: Perampanel 1mg with ketoconazole 400mg once daily for 10 days
Number of subjects: 26
Study 28535410 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole 400mg once daily for 10 days
Number of subjects: 26
Study 28535410 — intervention group
Group type: COMPARATOR
Intervention: Simulations with larger doses of ketoconazole (e.g., 200mg every 6h for 30 days)
Number of subjects: 26
Study 28535410 — intervention group
Group type: COMPARATOR
Intervention: Simulations with a more potent inhibitor than ketoconazole (e.g., itraconazole)
Number of subjects: 26
Study 25743541 — intervention group
Group type: EXPERIMENTAL
Intervention: Home game (HG)
Number of subjects: 297
Study 25743541 — intervention group
Group type: COMPARATOR
Intervention: Away game (AG)
Number of subjects: 297
Study 24155139 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (intravenous dose based on body weight every 2 or 4 weeks)
Number of subjects: 0
Study 24155139 — intervention group
Group type: COMPARATOR
Intervention: Tocilizumab
Number of subjects: 0
Study 21700013 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt containing Lactobacillus acidophilus La5 and Bifidobacterium lactis Bb12
Number of subjects: 60
Study 21700013 — intervention group
Group type: COMPARATOR
Intervention: Conventional yogurt
Number of subjects: 60
Study 19781318 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 60
Study 19781318 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Number of subjects: 60
Study 19781318 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 16818571 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate (5 mg daily)
Number of subjects: 124
Study 16818571 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6 (100 mg daily)
Number of subjects: 124
Study 16818571 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate and Vitamin B6 (combined)
Number of subjects: 124
Study 16818571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 16818571 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including placebo)
Number of subjects: 124
Study 14738330 — intervention group
Group type: EXPERIMENTAL
Intervention: Items rated as 'very important' by speech-language pathologists regarding patient satisfaction with dysphagia services.
Number of subjects: 0
Study 14738330 — intervention group
Group type: COMPARATOR
Intervention: Items not rated as 'very important' by speech-language pathologists.
Number of subjects: 0
Study 11140327 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba/Panax ginseng combination (60 mg GK501 and 100 mg G115)
Number of subjects: 256
Study 11140327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study 9007138 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 45 mg/m2 on days 1, 8, and 15 (level 1); 45 mg/m2 on days 1, 8, 15, 22, and 29 (level 2); 45 mg/m2 on days 1, 8, 15, 22, 29, 36, and 43 (level 3); 55 mg/m2 on days 1, 8, 15, 22, 29, 36, and 43 (level 4) with fixed dose radiotherapy (1.8 Gy/d for 6.5 weeks, total 59.4 Gy).
Number of subjects: 22
Study 1319619 — intervention group
Group type: EXPERIMENTAL
Intervention: Logiparin (2,500 anti-Xa units once daily)
Number of subjects: 1290
Study 1319619 — intervention group
Group type: EXPERIMENTAL
Intervention: Logiparin (3,500 anti-Xa units once daily)
Number of subjects: 1290
Study 1319619 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (5,000 IU twice daily)
Number of subjects: 1290
Study 6354937 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg three times daily
Number of subjects: 8
Study 6354937 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 8
Study 31843817 — intervention group
Group type: EXPERIMENTAL
Intervention: TTC (Teens Taking Charge)
Number of subjects: 60
Study 31843817 — intervention group
Group type: EXPERIMENTAL
Intervention: iP2P-TTC (iPeer2Peer integrated with Teens Taking Charge)
Number of subjects: 60
Study 31843817 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 60
Study 31843817 — intervention group
Group type: EXPERIMENTAL
Intervention: TTC and iP2P with TTC
Number of subjects: 60
Study 28709772 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation sessions on diet and physical activity and regular participation in walking groups
Number of subjects: 326
Study 28709772 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 326
Study 26662964 — intervention group
Group type: EXPERIMENTAL
Intervention: Gla‐300
Number of subjects: 243
Study 26662964 — intervention group
Group type: COMPARATOR
Intervention: Gla‐100
Number of subjects: 243
Study 24423921 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib 10 mg b.i.d. combined with FOLFIRI or FOLFOX
Number of subjects: 21
Study 24423921 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib 10 mg b.i.d. for 7 days followed by 7 days interruption
Number of subjects: 21
Study 24423921 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib 10 mg b.i.d. combined with chemotherapy
Number of subjects: 21
Study 23135184 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-osteotomy assisted lower incisor decompensation (G1)
Number of subjects: 22
Study 23135184 — intervention group
Group type: COMPARATOR
Intervention: Traditional pre-surgical decomposition (G2)
Number of subjects: 22
Study 20112006 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-aminopyridine (Fampridine-SR)
Number of subjects: 0
Study 20112006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18031439 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsubmerged surgical technique (198 implants)
Number of subjects: 77
Study 18031439 — intervention group
Group type: COMPARATOR
Intervention: Submerged surgical technique (206 implants)
Number of subjects: 77
Study 16048882 — intervention group
Group type: EXPERIMENTAL
Intervention: Public Access Defibrillation (PAD) Trial
Number of subjects: 61
Study 16048882 — intervention group
Group type: EXPERIMENTAL
Intervention: Social marketing techniques combined with behavior change models
Number of subjects: 61
Study 12152111 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 0
Study 12152111 — intervention group
Group type: EXPERIMENTAL
Intervention: Other ED therapies
Number of subjects: 0
Study 10196013 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment, 66.7 microgram/kg, administered subcutaneously three times weekly for 6 months
Number of subjects: 20
Study 10196013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7767692 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress inoculation group participants
Number of subjects: 108
Study 7767692 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction training group participants
Number of subjects: 108
Study 7767692 — intervention group
Group type: COMPARATOR
Intervention: Control group participants
Number of subjects: 108
Study 7767692 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminding older persons to use previously acquired training strategies
Number of subjects: 108
Study 7767692 — intervention group
Group type: COMPARATOR
Intervention: No reminder effects
Number of subjects: 108
Study 1291495 — intervention group
Group type: EXPERIMENTAL
Intervention: DL-carnitine (100 mg/kg/day in two divided doses orally for four days)
Number of subjects: 625
Study 1291495 — intervention group
Group type: COMPARATOR
Intervention: No carnitine (control group)
Number of subjects: 625
Study 6327139 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentils
Number of subjects: 10
Study 6327139 — intervention group
Group type: COMPARATOR
Intervention: Wholemeal bread and cottage cheese
Number of subjects: 10
Study 30874755 — intervention group
Group type: EXPERIMENTAL
Intervention: ACC/AHA guidelines (2008-2018)
Number of subjects: 6330
Study 30874755 — intervention group
Group type: EXPERIMENTAL
Intervention: ESC guidelines (2008-2018)
Number of subjects: 6330
Study 30874755 — intervention group
Group type: COMPARATOR
Intervention: Comparison of current vs prior ACC/AHA guidelines
Number of subjects: 6330
Study 30874755 — intervention group
Group type: COMPARATOR
Intervention: Comparison of current vs prior ESC guidelines
Number of subjects: 6330
Study 29471300 — intervention group
Group type: EXPERIMENTAL
Intervention: Zevalin (Yttrium-90-Ibritumomab Tiuxetan) after 2 cycles of ESHAP chemotherapy
Number of subjects: 28
Study 26901306 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular Dermal Matrix (ADM) plus Mineralized Bone Allograft (AB)
Number of subjects: 19
Study 26901306 — intervention group
Group type: COMPARATOR
Intervention: Acellular Dermal Matrix (ADM) only
Number of subjects: 19
Study 23344762 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg daily)
Number of subjects: 109
Study 23344762 — intervention group
Group type: COMPARATOR
Intervention: Non-aspirin group (discontinued aspirin >7 days before surgery)
Number of subjects: 109
Study 21798329 — intervention group
Group type: EXPERIMENTAL
Intervention: Active miswak
Number of subjects: 68
Study 21798329 — intervention group
Group type: COMPARATOR
Intervention: Inactive miswak
Number of subjects: 68
Study 19699454 — intervention group
Group type: EXPERIMENTAL
Intervention: 5mg of oxybutynin in sublingual form (Group O)
Number of subjects: 45
Study 19699454 — intervention group
Group type: COMPARATOR
Intervention: Placebo in tablet form (Group P)
Number of subjects: 45
Study 16394049 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with a history of unplanned pregnancy
Number of subjects: 424
Study 16394049 — intervention group
Group type: COMPARATOR
Intervention: Women without a history of unplanned pregnancy
Number of subjects: 424
Study 15636224 — intervention group
Group type: EXPERIMENTAL
Intervention: apo E allele frequency in AMD patients (epsilon4 - 11.11%, epsilon2 - 7.77%)
Number of subjects: 45
Study 15636224 — intervention group
Group type: COMPARATOR
Intervention: Control group allele frequency (epsilon4 - 13.6%, epsilon2 - 2.27%)
Number of subjects: 45
Study 11676227 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron (0.3 mg i.v.) administered 0.5 h before chemotherapy
Number of subjects: 30
Study 11676227 — intervention group
Group type: COMPARATOR
Intervention: Tropisetron (o.d. for 3 days)
Number of subjects: 30
Study 9196082 — intervention group
Group type: EXPERIMENTAL
Intervention: rhuMAb‐E25
Number of subjects: 19
Study 9196082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 1397884 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin, 400 mg orally or through a nasogastric tube, twice daily for 7 days
Number of subjects: 119
Study 3892729 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg/d
Number of subjects: 43
Study 3892729 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg/d
Number of subjects: 43
Study 31202003 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet and app-based gratitude intervention (5-week duration)
Number of subjects: 260
Study 31202003 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group (WLG)
Number of subjects: 260
Study 31202003 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet and app-based gratitude intervention
Number of subjects: 260
Study 29627596 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (1200 mg/day of eicosapentaenoic acid and 600 mg/day of docosahexaenoic acid)
Number of subjects: 80
Study 29627596 — intervention group
Group type: COMPARATOR
Intervention: Placebo pills
Number of subjects: 80
Study 29627596 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 80
Study 26814139 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring System (CGMS)
Number of subjects: 106
Study 26814139 — intervention group
Group type: COMPARATOR
Intervention: Self-Monitoring Blood Glucose (SMBG)
Number of subjects: 106
Study 25494622 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 62
Study 25494622 — intervention group
Group type: COMPARATOR
Intervention: Social contact control intervention
Number of subjects: 62
Study 22616181 — intervention group
Group type: EXPERIMENTAL
Intervention: Test preparation (Cyclosporin Soft Capsules)
Number of subjects: 24
Study 22616181 — intervention group
Group type: COMPARATOR
Intervention: Reference preparation (Cyclosporin Soft Capsules)
Number of subjects: 24
Study 20047624 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg daily
Number of subjects: 418
Study 20047624 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 12.5 mg daily
Number of subjects: 418
Study 20047624 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (atenolol and HCTZ)
Number of subjects: 418
Study 20047624 — intervention group
Group type: COMPARATOR
Intervention: Ambulatory Blood Pressure (ABP)
Number of subjects: 418
Study 20047624 — intervention group
Group type: COMPARATOR
Intervention: Office Blood Pressure (OBP)
Number of subjects: 418
Study 18821658 — intervention group
Group type: EXPERIMENTAL
Intervention: adalimumab + MTX
Number of subjects: 148
Study 18821658 — intervention group
Group type: COMPARATOR
Intervention: MTX alone
Number of subjects: 148
Study 16105427 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway Pressure Release Ventilation (APRV)
Number of subjects: 15
Study 16105427 — intervention group
Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 15
Study 12060436 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine 2 mg bid
Number of subjects: 228
Study 12060436 — intervention group
Group type: COMPARATOR
Intervention: Oxybutynin 5 mg bid
Number of subjects: 228
Study 10417452 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 0.75 mg plus alfentanil 0.125 mg (Group MA)
Number of subjects: 77
Study 10417452 — intervention group
Group type: COMPARATOR
Intervention: Morphine 1.5 mg alone (Group M)
Number of subjects: 77
Study 7555166 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical and surgical pleurodesis
Number of subjects: 35
Study 7555166 — intervention group
Group type: COMPARATOR
Intervention: Systemic corticosteroids for PCP treatment
Number of subjects: 35
Study 7555166 — intervention group
Group type: COMPARATOR
Intervention: Cigarette smoking and aerosolized pentamidine treatment
Number of subjects: 35
Study 2107519 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent administration of Haemophilus influenzae type b conjugate vaccine with measles-mumps-rubella vaccine
Number of subjects: 0
Study 2107519 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent administration of Haemophilus influenzae type b conjugate vaccine with diphtheria-tetanus-pertussis and oral poliovirus vaccines
Number of subjects: 0
Study 424753 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (intravenous administration)
Number of subjects: 40
Study 424753 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (control)
Number of subjects: 40
Study 31605793 — intervention group
Group type: EXPERIMENTAL
Intervention: NTX-010
Number of subjects: 50
Study 31605793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50